JP2020525407A5 - - Google Patents

Download PDF

Info

Publication number
JP2020525407A5
JP2020525407A5 JP2019566125A JP2019566125A JP2020525407A5 JP 2020525407 A5 JP2020525407 A5 JP 2020525407A5 JP 2019566125 A JP2019566125 A JP 2019566125A JP 2019566125 A JP2019566125 A JP 2019566125A JP 2020525407 A5 JP2020525407 A5 JP 2020525407A5
Authority
JP
Japan
Prior art keywords
composition according
per day
subject
composition
crofelemer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019566125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525407A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/035468 external-priority patent/WO2018222919A1/en
Publication of JP2020525407A publication Critical patent/JP2020525407A/ja
Publication of JP2020525407A5 publication Critical patent/JP2020525407A5/ja
Pending legal-status Critical Current

Links

JP2019566125A 2017-05-31 2018-05-31 先天性下痢障害を治療するための方法及び組成物 Pending JP2020525407A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513251P 2017-05-31 2017-05-31
US62/513,251 2017-05-31
PCT/US2018/035468 WO2018222919A1 (en) 2017-05-31 2018-05-31 Methods and compositions for treating congenital diarrhea disorder

Publications (2)

Publication Number Publication Date
JP2020525407A JP2020525407A (ja) 2020-08-27
JP2020525407A5 true JP2020525407A5 (enExample) 2021-07-26

Family

ID=64455032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566125A Pending JP2020525407A (ja) 2017-05-31 2018-05-31 先天性下痢障害を治療するための方法及び組成物

Country Status (12)

Country Link
US (2) US11857510B2 (enExample)
EP (1) EP3634581B8 (enExample)
JP (1) JP2020525407A (enExample)
CN (1) CN110831667A (enExample)
AU (1) AU2018278312B2 (enExample)
CA (1) CA3065797A1 (enExample)
DK (1) DK3634581T3 (enExample)
ES (1) ES2988850T3 (enExample)
FI (1) FI3634581T3 (enExample)
IL (1) IL270984B1 (enExample)
JO (1) JOP20190275A1 (enExample)
WO (1) WO2018222919A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
WO2021257089A1 (en) * 2020-06-19 2021-12-23 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214317B1 (fr) 1985-08-30 1988-08-17 Societe Des Produits Nestle S.A. Produit diététique à activité dépurative et anti-diarrhéique et son procédé de préparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
PT935417E (pt) 1996-10-16 2009-07-17 Napo Pharmaceuticals Inc Formulações entéricas de composições poliméricas antidiarreicas de proantocianidina
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
SG195538A1 (en) 2006-05-01 2013-12-30 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
EP2529626B1 (en) 2006-05-01 2017-11-22 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing colon cancer
US20120202876A1 (en) 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
CN103370101A (zh) 2010-10-31 2013-10-23 萨利克斯药品有限公司 用于治疗hiv相关性腹泻的方法和组合物
WO2017112953A1 (en) 2015-12-23 2017-06-29 Vanessa Research, Inc. Compositions and methods of treatment for mvid and related diseases
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي

Similar Documents

Publication Publication Date Title
Kim Short-chain fatty acids in ulcerative colitis
Alipoor et al. White adipose tissue browning in critical illness: a review of the evidence, mechanisms and future perspectives
JP6446134B2 (ja) 癌幹細胞治療用組成物
JP2020525407A5 (enExample)
TR201815668T4 (tr) Obezite tedavisine yönelik bileşikler ve bunların kullanım metotları.
JP2020523375A5 (enExample)
Klein Preventive and therapeutic efficacy of halofuginone-lactate against Cryptosporidium parvum in spontaneously infected calves: a centralised, randomised, double-blind, placebo-controlled study
JP2013536859A5 (enExample)
KR20220080120A (ko) 위장 건강 조성물
Alam et al. Efficacy of partially hydrolyzed guar gum-added oral rehydration solution in the treatment of severe cholera in adults
JP6360172B2 (ja) チグリンアルデヒドを使用する組成物及び方法
WO2015042821A1 (zh) 活化ampk的化合物及其使用
JP3604710B2 (ja) 骨粗鬆症予防及び治療剤
CN104001177A (zh) 一种治疗ii型糖尿病或代谢综合征的复方药物组合物
EP3979991B1 (en) Colonic release food supply as a coadjuvant in the treatment and prevention of colonic disorders caused by a suspected or confirmed alteration of the inflammatory pattern and microbiota destabilization
CN115884764A (zh) 用于治疗乙型冠状病毒感染的半胱胺前体化合物
Widjanarko et al. Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats
Duvoisin et al. Bromocriptine as an adjuvant to levodopa
Kume et al. THU0199 Tofacitinib improves left ventricular mass and cardiac output in patients with rheumatoid arthritis
US9532960B2 (en) Pharmaceutical composition and kit for applying metformin and sodium butyrate in Kras mutation cancer treatment
Fior et al. A Case of Non-Hodgkin's Lymphoma.
Shelotkar et al. A case study on Ritukala Shodhana (seasonal purification therapy) in childhood bronchial asthma
JP2019218317A (ja) 低体温の予防又は改善剤
JP2016183172A (ja) 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤
AU629520B2 (en) A medicament